Valsartan Improves Endothelial Dysfunction in Hypertension: A Randomized, Double-Blind Study by Tzemos, Nikolaos et al.
RESEARCH
Valsartan Improves Endothelial Dysfunction in Hypertension:
A Randomized, Double-Blind Study
Nikolaos Tzemos, Pitt O. Lim & Thomas M. MacDonald
Hypertension Research Centre, Division of Medicine and Therapeutics, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
Keywords
Amlodipine; Blood pressure; Endothelium;
Nitric oxide; Valsartan.
Correspondence
Dr. Nikolaos Tzemos, M.D., M.R.C.P. (UK),
Hypertension Research Centre, Division
of Medicine and Therapeutics, University of
Dundee, Ninewells Hospital and Medical School,




Re-use of this article is permitted in accordance




Endothelial dysfunction can predict cardiac outcomes in hypertension and re-
versing this abnormality has become an attractive therapeutic objective. We
tested the hypothesis that blocking the angiotensin type 1 (AT1) receptor with
valsartan in comparison with amlodipine would lead to an improvement in
forearm resistance artery endothelial dysfunction. In total, 25 hypertensive
subjects (mean age 60 years, SD 8) with a mean daytime ambulatory blood
pressure (BP) of 154 (10)/97 (6) mmHg were randomized following a 3-week
placebo run-in period to a double-blind, crossover trial of 16-week treatment
periods with either valsartan or amlodipine, separated by a 3-week washout
period. Intra-arterial infusions of acetylcholine (ACh) and NG-monomethyl-L-
arginine (L-NMMA) were used to assess stimulated and basal endothelium-
dependent nitric oxide (NO) release, respectively. Coinfusion of ACh and
L-NMMA was employed to investigate the existence of an NO-independent va-
sodilatory pathway. Valsartan and amlodipine each lowered the clinical BP to
the same extent (139 [7]/87 [6] and 139 [11]/89 [4] mmHg, respectively). The
vasodilatory response to ACh was signiﬁcantly increased with valsartan (max-
imal percentage change in forearm blood ﬂow (max.  FBF%) 301 [47] vs.
185 [34], mean [SEM]; P < 0.05) as compared with placebo, but remained un-
changed with amlodipine. Both valsartan and amlodipine similarly increased
the vasoconstrictive response to L-NMMA (max.  FBF% –43 [5], −42 [5],
respectively, vs. –26 [3] baseline; P < 0.001). The vasodilatory response after
coinfusion of ACh and L-NMMA was signiﬁcantly (P < 0.05) enhanced only
with valsartan. Valsartan reserved peripheral endothelial dysfunction through
both NO-dependent and -independent pathways, while for the same degree of
BP control, amlodipine had only a partial effect on NO bioactivity.
Introduction
An impairment of nitric oxide (NO) bioactivity or en-
dothelial dysfunction is an early feature found in small
resistance arteries of various vascular diseases, including
hypertension, and is often present before any structural
abnormality is evident [1,2]. Most, but not all, reports
have conﬁrmed the presence of endothelial dysfunc-
tion in essential and secondary hypertension [1–3] Al-
though the mechanisms of NO impairment in hyperten-
sion are likely to be complex and heterogeneous, they
are also desirable therapeutic targets since the presence
of endothelial dysfunction conveys an adverse cardiac
prognosis [4,5].
Recent research has focused on angiotensin II as a me-
diator of endothelial dysfunction in various cardiovas-
cular disorders [6,7]. Angiotensin II via the angiotensin
type 1 (AT1) receptor causes arteriolar vasoconstric-
tion and remodeling, superoxide anion production, renal
sodium reabsorption, aldosterone secretion, and en-
dothelin release, leading to increased vascular resistance
and promoting atherosclerosis [8,9]. Thus, AT1 receptor
activation limits NO bioactivity both by reducing NO re-
lease and by increasing NO inactivation. We investigated
the effects of AT1 receptor blockade, with valsartan, on
blood pressure (BP) and NO bioactivity in patients with
essential hypertension and compared this with calcium
channel blockade with amlodipine.
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Methods
Subjects
Twenty-ﬁve subjects (17 males and 8 postmenopausal fe-
males) with a mean age of 60 years (SD 8) and long-
standing, treated, uncomplicated essential hypertension
and without electrocardiographic or echocardiographic
evidence of left ventricular hypertrophy were recruited
from those attending the Tayside hypertension clinic. The
secondary causes of hypertension were excluded by his-
tory, physical examination, and biochemical and imaging
studies, where clinically indicated. Patients with a his-
tory of coronary artery disease, diabetes, hyperlipidemia
(total cholesterol >5.0 mmol/L), renal impairment, or
other vascular diseases were also excluded. Twenty-ﬁve
healthy volunteers matched for sex and age recruited
through advertisement within our institution constituted
the control comparison group. The study was approved
by the Tayside ethics committee.
Study Protocol
This was a randomized, double-blind, placebo-controlled
crossover study. The patients were randomized to re-
ceive either valsartan or amlodipine in a crossover de-
sign, each for 16 weeks, with a 3-week washout period
between treatments. After randomization, all antihyper-
tensive drugs (Table 1) were withdrawn, and the subjects
entered a 3-week placebo run-in period. None of the pa-
tients, either before or during the study, were taking any
medication known to affect the vascular endothelium. At
the end of the 3-week placebo run-in period, all subjects
underwent a 24-h ambulatory blood pressure monitor-
ing (ABPM) (Table 2). Also, vascular endothelial function
assessment and blood sampling took place at the end of
the same period (baseline). The subjects were then ran-
domized to 16-week treatment periods of either valsartan
80 mg or amlodipine 5 mg. The subjects returned sub-
sequently to the laboratory after 4 weeks in each active
treatment period. If their BP was >140/90 mmHg, then
the study medication was uptitrated to 160 mg for val-
sartan or 10 mg for amlodipine. Finally, at the end of
Table 1 Previous antihypertensive treatment of the study population
Number (percentage) of patients Previous antihypertensive therapy
14 (56) βeta receptor blocker (atenolol)
6 (24) Calcium channel blocker (amlodipine)
5 (20) ACE-I (lisinopril)
6 (24) Combination with thiazide diuretic
ACE-I indicates angiotensin-converting enzyme inhibitor.
Table 2 Hemodynamic data during the study
Variable Baseline (placebo) Amlodipine Valsartan
24-h SBP, mmHg 155 (3) 135 (3)∗ 136 (4)∗
24-h DBP, mmHg 92 (3) 84 (3)∗ 83 (2)∗
Daytime SBP, mmHg 151 (11) 138 (4)∗ 139 (4)∗
Daytime DBP, mmHg 97(3) 87 (4)∗ 88 (3)∗
Clinical SBP, mmHg 162 (13) 139 (11)∗ 139 (7)∗
Clinical DBP, mmHg 103 (8) 87 (6)∗ 89 (4)∗
Heart rate, beats/min 75 (9) 76 (12) 79 (12)
Absolute basal FBF 3 (0.2) 3.1 (0.3) 3.1(0.2)
24-h indicates daytime and nighttime ambulatory blood pressure
monitoring, respectively, for systolic blood pressure (SBP) and diastolic
blood pressure (DBP). FBF indicates forearm blood ﬂow expressed in
mL/min/100 mL forearm volume.
Values are expressed as mean (SD).
∗P < 0.05 versus baseline (placebo).
each active treatment, a further 3-week placebo period
(washout) was implemented prior to crossing over to the
alternative drug.
Clinical BP was measured (a mean of three mea-
surements) at the beginning of each visit after 10-min
rest in seated position using a semiautomatic oscillo-
metric monitor (OMRON 705CP; Matsusaka, Matsusaka-
City, Japan). ABPM was recorded using SpaceLabs model
90207 recorders (Redmond, Washington, DC, USA).
Recordings were taken every 15 min during the daytime
(8.00 a.m. to 10.00 p.m) and every 30 min during the
nighttime (10.00 p.m. to 8.00 a.m.). During ABPM, the
subjects were asked to continue their normal daily life
activities.
Vascular Studies
Vascular studies took place at the end of the 3-week
placebo run-in period (baseline) and at the end of each
16-week active treatment; thus, each subject underwent,
in total, three endothelial function assessments. All vas-
cular studies were conducted by the same operator (N.T.)
after an overnight fast and in a quiet, temperature-
controlled laboratory (24 ± 0.5◦C) with dimmed lights.
Alcohol and caffeine-containing beverages were avoided
for at least 24 h before the study day. Following a supine
rest of 30 min, the nondominant brachial artery was
cannulated with a 27-gauge steel needle mounted onto
a 16-gauge polyethylene epidural catheter under local
anesthesia with 1% lidocaine. Forearm blood ﬂow (FBF)
was measured simultaneously in both arms by strain-
gauge venous occlusion plethysmography, as previously
described [10]. BP and heart rate were noninvasively
(HEM-705CP; OMRON, Matsusaka-City, Japan) recorded
in the noninfused (control) arm before each infusion.
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Hemodynamic Measurements
and Drug Infusions
FBF was measured during the last 2 min after each in-
fusion period and expressed as mL/min/100 mL fore-
arm volume according to the Whitney method [11].
Resting baseline FBF values were obtained at least 30
min after needle placement to ensure that the blood
ﬂow in the cannulated arm had stabilized. After rest-
ing baseline FBF measurements, each study subject re-
ceived intra-arterial infusions of incremental doses of
acetylcholine (ACh, Miochol; CIBAVision, Southamp-
ton, UK), sodium nitroprusside (SNP; David Bull Labo-
ratories, Warwick, UK), and NG-monomethyl-L-arginine
(L-NMMA; Clinalfa, L¨ aufelﬁngem, Switzerland). The
muscarinic agonist ACh was used to assess endothelium-
dependent vasodilatation (stimulated NO release), while
SNP, an exogenous source of NO, was used to as-
sess endothelium-independent vasodilatation. Cumula-
tive dose response curves were constructed after infu-
sions of ACh at 25, 50, and 100 nmol/min and SNP at 4.2,
12.6, and 37.8 nmol/min, each incremental dose for 5
min. The endothelial-dependent vasoconstriction was as-
sessed using the competitive nitric oxide synthase (NOS)
antagonist L-NMMA infused at 1, 2, and 4 μmol/min,
again, each for 5 min. After each agent, care was taken
for FBF to reach the baseline values, generally at least
after 30 min. To assess the presence of NO-independent
pathway in achieving resistance artery vasodilation,
L-NMMA infusion was kept constant at 4 μmol/min for
further 10 min. Then, ACh at 50 and 100 mol/min, each
for 5 min, was coinfused with L-NMMA and respective
dose–response curves were constructed. The order of the
vasoactive drugs infused was identical in all the study vis-
its. Drugs, saline, and 5% dextrose were infused at ﬂow
rates of 1 mL/min by means of a constant-rate infusion
pump (Braun, Shefﬁeld, UK). All studies were performed
by the same operator (N.T.), blinded to the other mea-
surements.
Statistical Analysis
Five recordings at each infusion step were measured for
both the infused and the control arms. Because BP and
baseline FBFs did not vary signiﬁcantly during the visits,
FBF ratio between the infused and the control arm in re-
sponse to drugs was expressed as a percentage of the ratio
measured during the control period (percentage change
in FBF,  FBF% [mean ± SEM]). From previous studies,
the sample size was estimated to have a power of 90%
to detect a cumulative  FBF% difference between treat-
ments of 100%. Clinical characteristics between clinic vis-
its were compared by Student’s paired t-test, while FBF
measurements for individual treatments were compared
between the treatments by a two-way ANOVA with re-
peated measures, with correction for multiple compar-
isons for within-group effects. The Wilcoxon rank-sum
test was used when variables were not normally dis-
tributed. A two-tailed P < 0.05 was considered signiﬁ-
cant. Sensitivity and reproducibility of the methods per-
formed in our laboratory have been previously reported
[10].
Results
Clinical and Biochemical Characteristics
Daytime ABPM (Table 2) at the end of the 3-week
placebo run-in period conﬁrmed mild-to-moderate es-
sential hypertension [12]. There were no signiﬁcant
differences in baseline plasma electrolytes or choles-
terol levels between the three study periods (Table 3).
A signiﬁcant reduction in plasma aldosterone was ob-
served only with valsartan treatment compared with
baseline (placebo) (Table 2). Ninety percent of all patients
in each treatment group required their antihypertensive
therapy titrated to a double dose.
At the end of the each 16-week treatment period, both
valsartan and amlodipine reduced systolic and diastolic
BP to the same extent compared with placebo (baseline)
(Table 2).
Baseline FBF Responses
Patients with hypertension had a blunted vasodilatory re-
sponse to ACh as compared with normotensive patients
(P < 0.01 for cumulative dose), while the vasodilatory
response to SNP, a surrogate of endothelial-independent
vasodilation, was not different between the two groups
(Figure 1). Similarly, the vasoconstrictive response was
signiﬁcantly blunted in hypertensive patients (P < 0.05
Table 3 Biochemical parameters during the study
Variable Baseline (placebo) Amlodipine Valsartan
Serum potassium, mmol/L 4.1 (0.3) 4.0 (0.2) 4.2 (0.3)
Serum creatinine, μmol/L 95 (10) 94 (12) 93 (10)
Plasma urate, mmol/L 0.34 (0.3) 0.30 (0.3) 0.34 (0.3)
Plasma glucose, mmol/L 4.9 (0.3) 5.1 (0.7) 4.8 (0.6)
Total cholesterol, mmol/L 4.8 (0.8) 4.9 (0.6) 4.8 (0.5)
Plasma aldosterone, pg/mL 136 (20) 126 (22) 75 (20)∗
Values are expressed as mean (SD).
∗P < 0.05 versus baseline (placebo).
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Figure 1 Percentage changes in forearm blood ﬂow (FBF) ratio (infused/noninfused) from baseline preceding each drug infusion for three dose levels
of (A) acetycholine, (B) sodium nitroprusside, and (C) L-NMMA and (D) coinfusion of acetylcholine and L-NMMA in normotensive control group ()a n d
hypertensive patients (), respectively. Values are mean (SEM). ∗P < 0.05, †P < 0.001 for differences between the treatments.
for cumulative dose; Figure 1). Coinfusion of L-NMMA
and ACh produced signiﬁcantly attenuated vasodilation
in the normotensive group and, to lesser extent, in the
hypertensive group (P < 0.05 for cumulative maximum
 FBF%; Figure 1).
FBF Responses during Antihypertensive
Therapy
Valsartan produced a signiﬁcant dose-dependent increase
in forearm vasodilatory reponse to ACh as compared
with baseline (maximum  FBF% 301 [47] vs. 185 [34],
mean [SEM]: P < 0.01 for the difference between the
whole-dose–response curves; Figure 2). In comparison,
amlodipine had no signiﬁcant effect on ACh vasodila-
tory response ( FBF% 210 [54] vs. 185 [34], P =
0.63; Figure 2). Neither valsartan nor amlodipine af-
fected the vascular response to SNP signiﬁcantly, sug-
gesting that the vasodilatory NO-independent pathway
remained unaffected (Figure 2). The vasoconstrictive re-
sponse to exogenous NOS inhibitor L-NMMA was simi-
larly and signiﬁcantly enhanced with both valsartan and
amlodipine compared with baseline (maximum  FBF%
–43 [5], −42 [5], respectively, vs. –26 [3]; P < 0.05;
Figure 2). Finally, during valsartan therapy, coinfusion
of ACh and L-NMMA led to a signiﬁcant increase in
maximal  FBF% and thus to vasodilation in compar-
ison to amlodipine therapy (Figure 2). Since pharma-
cologically evoked NO release was maximally exploited
during coinfusion of ACh and L-NMMA, we specu-
late that the signiﬁcant difference in FBF between the
valsartan and the amplodipine periods was secondary
to the existence of a NO-independent vasodilatory
pathway.
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Figure 2 Percentage changes in forearm blood ﬂow (FBF) ratio (infused/noninfused) from baseline preceding each drug infusion for three dose levels
of (A) acetycholine, (B) sodium nitroprusside, and (C) L-NMMA and (D) coinfusion of acetylcholine and L-NMMA after placebo (•), valsartan (), and
amlodipine () treatment periods, respectively. Values are mean (SEM). ∗P < 0.05, †P < 0.001 for differences between the treatments.
Discussion
Our study has two novel ﬁndings. First, we have shown
that after a sufﬁciently long period of antihypertensive
therapy with either valsartan or amlodipine and for the
same BP control, only valsartan improved both stimu-
lated and basal NO release. Second, and for the ﬁrst
time, we have shown that valsartan modulated forearm
resistance artery endothelial function through the NO-
independent mechanism.
Endothelial Dysfunction in Hypertension and
Renin–Angiotensin–Aldosterone System (RAAS)
Hypertension is a disease in which the systemic arter-
ies are both structurally and functionally abnormal [13].
Apart from structural changes, the arterial wall also
exhibits functional abnormalities such as impaired NO
bioactivity or endothelial dysfunction [2]. Angiotensin
II acting via the AT1 receptor has a direct vasocontric-
tive effect [14]: it promotes endothelin (ET-1) synthesis
and release from the endothelial cells, thus causing vaso-
constriction, and reduces NO release, thus increasing pe-
ripheral vascular resistance [15]. In addition, angiotensin
II enhances NO inactivation via an increase in oxida-
tive stress through NADP/NADPH activation [9]. It is
conceivable that AT1 receptor blockade could prevent
these adverse effects of angiotensin II on endothelial NO
bioavailability.
AT1 Receptor Blockade and Endothelial
Function in Hypertensive Patients
Our study conﬁrms previous reports of the beneﬁcial ef-
fect of AT1 receptor blockade on vascular endothelium
in those patients with documented atherosclerosis and
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also in hypertensive patients [7,16]. Schiffrin and col-
leagues [16] have shown that long-term treatment with
another AT1 receptor blocker, losartan, improved both
structural and functional properties of small resistance ar-
teries in patients with essential hypertension. More re-
cently, Klingbeil et al. [17] have shown in a carefully
conducted double-blind, placebo controlled study that
6 weeks of oral valsartan therapy also favorably affected
basal NO but had no effect on stimulated NO release.
It is possible that a short duration of valsartan therapy
(6 weeks compared with 16 weeks) might have been re-
sponsible for the lack of improvement in ACh-evoked
vascular response. However, not all studies involving AT1
receptor blockers have had the same impact on NO bioac-
tivity. Ghiadoni and colleagues [6] have reported that
AT1 receptor blockade with candesartan improved basal
and stimulated NO release in essential hypertensive pa-
tients. However, the improvement in stimulated NO re-
lease was associated with a concomitant enhancement
of the SNP vasodilatory response; thus, improvement of
both functional and structural properties of the arterial
wall was evident. The patients involved in their study
were highly selected and were mainly untreated (and
probably had a shorter duration of hypertension), which
may account for the disparity between their ﬁndings and
ours. Also, we speculate that the different pharmacoki-
netic and pharmacodymamic properties of agents within
the same class might have a profound difference on their
biological effect, as in the case of angiotensin-converting
enzyme (ACE) inhibitors [18].
Mechanism(s) of Endothelial Dysfunction
Reversal
The ﬁnding that valsartan therapy produced signiﬁcant
vasodilation during coinfusion of ACh and L-NMMA is
intriguing. Additional vasodilation following coinfusion
of ACh and L-NMMA suggests the existence of a non-NO
pathway responsible for this effect. Although, not readily
obvious from our study, it is possible that valsartan might
have modulated peripheral endothelial function through
a cyclo-oxygenase mechanism [19] and/or through the
release of the elusive endothelium-derived hyperpolariz-
ing factor (EDHF) [20]. Clearly, the above ﬁnding merits
further studies.
Another possible and equally intriguing explanation
is the blunting of the oxidative stress by valsartan. Ox-
idative stress affects NO bioactivity by reducing over-
all availability of locally released NO, both by acceler-
ating NO deactivation and by reducing the disposal of
essential eNOS precursors and cofactors such as BH4 and
arginine [21]. In support of this mechanism, Hirooka
and colleagues [22] have recently shown that valsartan
therapy improved large-artery endothelial dysfunction by
modulation of oxidative stress, evidenced as reduction of
urinary excretion of metabolites directly involved in ox-
idative stress. In the same study, amlodipine had no
appreciable effect on the markers of oxidative stress.
Similarly, Aslam and colleagues [23] have shown that
valsartan therapy signiﬁcantly reduced plasma levels of
asymmetric dimethylarginine (ADMA)—an endogenous
inhibitor of NOS—and other plasma oxidative markers in
hypertensive patients with end-stage renal disease.
Last, in our study, plasma levels of aldosterone, a min-
eralocorticoid, were signiﬁcantly reduced by valsartan
but not by amlodipine. Mineralcorticoids are known to
enhance vascular responsiveness to pressor agents such
as norepinephrine and angiotensin II even before sys-
temic BP begins to increase [24,25]. In support of this,
Taddei and colleagues [3] have reported that in pa-
tients with primary hyperaldosteronism, surgical excision
of aldosterone-secreting adrenal adenomas normalized
the vascular response to ACh, while the SNP response
remained unchanged. It is possible that the signiﬁcant
reduction in plasma aldosterone achieved only during
valsartan treatment might have been responsible for the
improvement of both stimulated and basal NO release as
compared with amlodipine treatment, despite the same
blood pressure control achieved with both agents.
Do Diverse Mechanisms of Endothelial Function
Improvement Translate into Clinical Beneﬁt?
Endothelial dysfunction has been shown to predict
cardiac outcomes in hypertension. However, whether
reversing this abnormality could have an impact on clin-
ical beneﬁt over and above that of BP and other risk fac-
tors has not been investigated. Nevertheless, reduction
of vascular remodeling achieved through NO- dependent
and -independent pathways may be an important goal to
decrease cardiovascular risk, particularly in high-risk pa-
tients, such as those with metabolic syndrome or with
clusters of cardiovascular risk factors, as found in patients
with hypertension and diabetes. Perhaps, we could cau-
tiously speculate that the signiﬁcant reduction of devel-
oping diabetes mellitus in high-risk hypertensive patients
during valsartan therapy recently seen in the Valsartan
Antihypertensive Long-Term Use Evaluation (VALUE)
study [26] might have been secondary to the favorable
effects of valsartan exerted on vascular endothelium.
Study Limitations
It could be argued that the difference in the results be-
tween amlodipine and valsartan might have been as a re-
sult of carryover effects. We think this is unlikely for two
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main reasons. First, BP after the second placebo period
(washout) was similar in both treatment groups and was
similar to that after the initial placebo run-in period (data
not shown). Second, absolute FBFs between the two ac-
tive treatment periods and placebo (baseline) were not
different (Table 2).
Conclusions
The present study found that valsartan, but not amlodip-
ine, improved the functional properties of the resistance
vessels in essential hypertension through a mechanism
that was additional to that seen in BP reduction.
Conﬂict of Interest
Thomas M. MacDonald has served on advisory boards
for Novartis and was the UK coordinator for the VALUE
study. Also, the same author has received research fund-
ing from Novartis to study the effects of valsartan in heart
failure with normal left ventricular systolic function.
References
1. Calver A, Collier J, Moncada S, Vallance P. Effect of local
intra-arterial NG-monomethyl-L-arginine in patients with
hypertension: The nitric oxide dilator mechanism appears
abnormal. J Hypertens 1992;10:1025–1031.
2. Panza JA, Quyyumi AA, Brush JE Jr., Epstein SE.
Abnormal endothelium-dependent vascular relaxation in
patients with essential hypertension. N Engl J Med
1990;323:22–27.
3. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to
acetylcholine in primary and secondary forms of human
hypertension. Hypertension 1993;21:929–933.
4. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R.
Prognostic role of reversible endothelial dysfunction in
hypertensive postmenopausal women. JA mC o l lC a r d i o l
2002;40:505–510.
5. Perticone F, Ceravolo R, Pujia A, et al. Prognostic
signiﬁcance of endothelial dysfunction in hypertensive
patients. Circulation 2001;104:191–196.
6. Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A.
Effect of the angiotensin II type 1 receptor blocker
candesartan on endothelial function in patients with
essential hypertension. Hypertension 2000;35:501–506.
7. Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and
chronic angiotensin-1 receptor antagonism reverses
endothelial dysfunction in atherosclerosis. Circulation
2000;101:2349–2354.
8. Dzau VJ. Local expression and pathophysiological role of
renin-angiotensin in the blood vessels and heart. Basic Res
Cardiol 1993;88:1–14.
9. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander
RW. Angiotensin II stimulates NADH and NADPH oxidase
activity in cultured vascular smooth muscle cells. Circ Res
1994;74:1141–1148.
10. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses
endothelial dysfunction in essential hypertension: A
randomized, double-blind, crossover study. Circulation
2001;104:511–514.
11. Whitney RJ. The measurement of volume changes in
human limbs. J Physiol 1953;121:1–27.
12. Williams B, Poulter NR, Brown MJ, et al. Guidelines for
management of hypertension: Report of the fourth
working party of the British Hypertension Society,
2004-BHS IV. J Hum Hypertens 2004;18:139–185.
13. Raij L. Hypertension, endothelium, and cardiovascular
risk factors. A mJM e d1991;90:13S–18S.
14. Touyz RM, He G, Deng LY, Schiffrin EL. Role of
extracellular signal-regulated kinases in angiotensin II-
stimulated contraction of smooth muscle cells from
human resistance arteries. Circulation 1999;99:392–399.
15. Fyhrquist F, Metsarinne K, Tikkanen I. Role of
angiotensin II in blood pressure regulation and in the
pathophysiology of cardiovascular disorders. JH u m
Hypertens 1995;9(Suppl 5):S19–S24.
16. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction
of arterial structure and endothelial dysfunction in
human essential hypertension by the angiotensin receptor
antagonist losartan. Circulation 2000;101:1653–1659.
17. Klingbeil AU, John S, Schneider MP, Jacobi J, Weidinger
G, Schmieder RE. AT1-receptor blockade improves
augmentation index: A double-blind, randomized,
controlled study. J Hypertens 2002;20:2423–2428.
18. Anderson TJ, Elstein E, Haber H, Charbonneau F.
Comparative study of ACE-inhibition, angiotensin II
antagonism, and calcium channel blockade on
ﬂow-mediated vasodilation in patients with coronary
disease (BANFF study). JA mC o l lC a r d i o l2000;35:60–66.
19. Schmidt B, Drexler H, Schieffer B. Therapeutic effects of
angiotensin (AT1) receptor antagonists: Potential
contribution of mechanisms other than AT1 receptor
blockade. Am J Cardiovasc Drugs 2004;4:361–368.
20. Fujii K, Tominaga M, Ohmori S, Kobayashi K, Koga T,
Takata Y, Fujishima M. Decreased endothelium-
dependent hyperpolarization to acetylcholine in smooth
muscle of the mesenteric artery of spontaneously
hypertensive rats. Circ Res 1992;70:660–669.
21. Paolocci N, Biondi R, Bettini M, et al. Oxygen
radical-mediated reduction in basal and agonist-evoked
NO release in isolated rat heart. J Mol Cell Cardiol
2001;33:671–679.
22. Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K.
Effects of valsartan or amlodipine on endothelial function
and oxidative stress after one year follow-up in patients
with essential hypertension. Clin Exp Hypertens
2008;30:267–276.
Cardiovascular Therapeutics 27 (2009) 151–158 c   2009 Blackwell Publishing Ltd 157Valsartan and Endothelial Dysfunction N. Tzemos et al.
23. Aslam S, Santha T, Leone A, Wilcox C. Effects of
amlodipine and valsartan on oxidative stress and plasma
methylarginines in end-stage renal disease patients on
hemodialysis. Kidney Int 2006;70:2109–2115.
24. Gomez-Sanchez EP. Central hypertensive effects of
aldosterone. Front Neuroendocrinol 1997;18:440–
462.
25. Pirpiris M, Sudhir K, Yeung S, Jennings G, Whitworth JA.
Pressor responsiveness in corticosteroid-induced
hypertension in humans. Hypertension 1992;19:567–574.
26. Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan
compared to amlodipine on preventing type 2 diabetes in
high-risk hypertensive patients: The VALUE trial.
J Hypertens 2006;24:1405–1412.
158 Cardiovascular Therapeutics 27 (2009) 151–158 c   2009 Blackwell Publishing Ltd